marked.bio

Company

Shanghai JMT-Bio

4 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 3 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

osimertinib 3JMT101 2JSKN003 1regorafenib 1fruquintinib 1glumetinib 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

4 of 6 trials shown

  1. JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan

    Not yet recruiting Phase 3 Shanghai JMT-Bio Started 2026Primary completion 2027-11 NCT07384377

    JSKN003trifluridine/tipiracilregorafenibfruquintinib

    …reatment with oxaliplatin, 5-fluorouracil (such as 5-FU, Capecitabine) , irinotecan (DMMR/MSI-H subjects also need anti-PD-1/PD-L1 antibody treatment failure).

    MSI-H / dMMRHER2-positive Colorectal Cancer

  2. Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

    Not yet recruiting Phase 2/3 Shanghai JMT-Bio Started 2025Primary completion 2028-12 NCT06908772

    glumetinibosimertinib FDA EU

    …ined With Osimertinib as First-Line Treatment in Non-Small Cell Lung Cancer Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

    EGFR exon 19 deletion / L858RRecurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

  3. JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

    Not yet recruiting Phase 3 Shanghai JMT-Bio Started 2024Primary completion 2027-03 NCT06380348

    JMT101osimertinibcisplatinpemetrexed

    For central laboratory confirmation of EGFR exon 20 insertion mutation with tumour tissue/blood sample.

    EGFR exon 20 insertionStatus may be outdated, last updated 2024-04-23Local Advanced or Metastatic NSCLC

  4. JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

    Active, not recruiting Phase 2 Shanghai JMT-Bio Started 2021Primary completion 2023-05 NCT06391944

    JMT101osimertinib FDA EU

    … to the 8th edition of the AJCC TNM staging criteria) or metastatic (Stage IV) harbouring EGFR common mutation with tumour tissue/blood sample.

    EGFR exon 19 deletion / L858RStatus may be outdated, last updated 2024-04-30Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation